Jaclyn is a health economist with more than 12 years of experience supporting the public sector, including provincial governments, cancer agencies and health technology assessment committees. She led the Pharmacoeconomics Research Unit at Cancer Care Ontario and Ontario Health providing objective advice and evidence to guide public drug program policy and planning. She has extensive technical and strategic expertise in pharmacoeconomics and has developed more than 20 submissions to provincial and pan-Canadian drug review processes to address unfunded gaps in the system. Jaclyn has worked closely with CADTH’s pan-Canadian Oncology Drug Review (pCODR) to interpret and improve economic content in the drug review process, and with the pan-Canadian Pharmaceutical Alliance (pCPA) to develop innovative support tools for integrating economic information into negotiations. She has played an active role in exploring and expanding the generation and use of real-world evidence (RWE) in cancer drug funding as a core member of the Canadian Real-World Evidence for value of Cancer Drugs (CanREValue) Collaboration and has experience developing oncology RWE studies using administrative databases from across Canada.